Multi-omic profiling of metastatic lesions to guide treatment selection: The Side Out 2 trial experience.
Mariaelena Pierobon(George Mason University), Stephen P. Anthony, Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia Wulfkuhle(University of California, San Francisco), Linda Vocila(Translational Genomics Research Institute), Ariane Kemkes, Donald W. Northfelt(Mayo Clinic in Arizona), Rosa I. Gallagher(George Mason University), David W. Craig(City of Hope), Nicholas J. Robert(Tufts Medical Center), Amber Conrad(Translational Genomics Research Institute), John D. Carpten(City of Hope), Lance A. Liotta(George Mason University), Jessica Aldrich(Translational Genomics Research Institute), Shukmei Wong(Translational Genomics Research Institute), David Loesch(Caris Life Sciences (United States)), David Arguello(Caris Life Sciences (United States)), Bryant Dunetz(Side-Out Foundation), K. Alex Hodge(George Mason University), Mohammad Jahanzeb(Florida Atlantic University)
Cited by 4
Related Papers
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth
|Journal of Clinical Investigation|2005|524
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth
|Journal of Clinical Investigation|2005|508